Source:http://linkedlifedata.com/resource/pubmed/id/19450896
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-2-1
|
| pubmed:abstractText |
This study investigated the immunomodulatory effects of low-dose interferon-alpha (IFN-alpha) in a cohort of 21 stage II or III melanoma patients treated in an adjuvant setting. Serial assessments in peripheral blood were performed at baseline and at regular intervals. Depletion of CD3+CD4+ T cells was predominant within the "central memory" and "memory" subsets. The impact of IFN-alpha was more marked at the level of all CD3+CD8+ T-cell subsets that showed a sustained and significant decrease. Both myeloid and plasmacytoid dendritic cell (DC) subsets were depleted, but the MDC/PDC ratio tended to increase 12 months after treatment. Also, CD14+CD16+ monocytes showed a significant increase of both MHC class I and the CD86 costimulatory molecule. IP-10/CXCL10 plasma levels significantly increased already at 3 months of therapy and remained at significantly high levels during the study period. The dramatic increase of IP-10/CXCL10 inversely correlated with a significant decrease of the CXCR3+CD8+ T lymphocytes. Low-dose IFN-alpha therapy can significantly affect phenotypic and functional properties of blood circulating lymphocytes and antigen-presenting cells, and production of IP-10/CXCL10, that appear to be important for the orchestration of an effective immune response during adjuvant IFN-alpha therapy for melanoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/CXCR3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CXCL10,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CXCR3,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b,
http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1878-3279
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
215
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
113-23
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:19450896-Adjuvants, Immunologic,
pubmed-meshheading:19450896-Adult,
pubmed-meshheading:19450896-Aged,
pubmed-meshheading:19450896-Antigens, CD3,
pubmed-meshheading:19450896-Chemokine CXCL10,
pubmed-meshheading:19450896-Cohort Studies,
pubmed-meshheading:19450896-Female,
pubmed-meshheading:19450896-France,
pubmed-meshheading:19450896-Humans,
pubmed-meshheading:19450896-Immunomodulation,
pubmed-meshheading:19450896-Interferon-alpha,
pubmed-meshheading:19450896-Lymphocyte Count,
pubmed-meshheading:19450896-Male,
pubmed-meshheading:19450896-Melanoma,
pubmed-meshheading:19450896-Middle Aged,
pubmed-meshheading:19450896-Neoplasm Staging,
pubmed-meshheading:19450896-Polyethylene Glycols,
pubmed-meshheading:19450896-Receptors, CXCR3,
pubmed-meshheading:19450896-Recombinant Proteins,
pubmed-meshheading:19450896-Skin Neoplasms,
pubmed-meshheading:19450896-T-Lymphocyte Subsets
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.
|
| pubmed:affiliation |
Laboratoire d'Immunologie des Tumeurs, Institut Paoli-Calmettes, Université de la Méditerranée, INSERM UMR 599, 232 Bd. Sainte Marguerite, Marseille Cedex 09, France.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|